Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Niagen Bioscience, Inc. - Common Stock
(NQ:
NAGE
)
5.545
-0.545 (-8.95%)
Streaming Delayed Price
Updated: 3:18 PM EST, Feb 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Niagen Bioscience, Inc. - Common Stock
Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science
January 29, 2026
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.
From
Equity Insider
Via
GlobeNewswire
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
January 15, 2026
From
Niagen Bioscience, Inc
Via
Business Wire
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
January 21, 2026
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.
From
USA News Group
Via
GlobeNewswire
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
December 22, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
November 13, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Announces $10 Million Share Repurchase Program
November 06, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
November 12, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
November 04, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
October 06, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide
October 01, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
September 16, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
August 06, 2025
From
Niagen Bioscience, Inc.
Via
Business Wire
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 04, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
July 23, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
July 14, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
July 08, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
June 20, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience to Participate in the BIO 2025 International Convention
June 11, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
June 09, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
June 04, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
May 07, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
May 05, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
April 29, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
April 28, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
April 07, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
March 20, 2025
From
Niagen Bioscience, Inc
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
